The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kochetov A.G.

Tsentr kardiokhirurgii i tsentr urologii 3-go Tsentral'nogo voennogo klinicheskogo gospitalia im. A.A. Vishnevskogo MO RF, Moskovskaia oblast', Krasnogorsk

Lyang O.V.

Assotsiatsija spetsialistov i organizatsij laboratornoj sluzhby «Federatsija laboratornoj meditsiny», 127083 Moskva, ul. 8 Marta, 1, str.12

Gimadiev R.R.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Abramov A.A.

National Cardiology Research Center, Russian Ministry of Health, 3 Cherepkovskaya 15A, Moscow, 121552, Russian Federation

Zhirov I.V.

National medical research center of cardiology MH RF

Skvortsov A.A.

Federal State Budget Organization National Medical Research Center of Cardiology, Ministry of Healthcare Russian Federation, Moscow, Russia

Zaseeva A.V.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Bosykh E.G.

Russian Cardiology Research and Production Complex of the Ministry of Healthcare of the Russian Federation

Masenko V.P.

National Medical Research Center of Cardiology, Ministry of Healthcare of Russia

Tereshchenko S.N.

National medical research center of cardiology MH RF

Assessment of circulating microRNA expression in patients with cardiovascular pathology

Authors:

Kochetov A.G., Lyang O.V., Gimadiev R.R., Abramov A.A., Zhirov I.V., Skvortsov A.A., Zaseeva A.V., Bosykh E.G., Masenko V.P., Tereshchenko S.N.

More about the authors

Journal: Laboratory Service. 2016;5(2): 28‑31

Read: 836 times


To cite this article:

Kochetov AG, Lyang OV, Gimadiev RR, et al. . Assessment of circulating microRNA expression in patients with cardiovascular pathology. Laboratory Service. 2016;5(2):28‑31. (In Russ.)
https://doi.org/10.17116/labs20165228-31

Recommended articles:
Modern stra­tegies for early diagnosis of cardiotoxicity caused by chemotherapy. Russian Journal of Preventive Medi­cine. 2025;(11):113-120
Possibilities of inte­ractions of circular RNAS with nucleic acids and proteins. Mole­cular Gene­tics, Microbiology and Viro­logy. 2025;(4-2):28-32

References:

  1. Kochetov A, Zhirov I, Masenko V, Gimadiev R, Lyang O, Tereshchenko S. Prospects of use of microRNAs in the diagnostics and treatment of heart failure. Kardiologicheskii vestnik. 9(2):62-67. (In Russ.)
  2. Bartel B. MicroRNAs directing siRNA biogenesis. Nat Struct Mol Biol. 2005;12(7):569-571.  doi:10.1038/nsmb0705-569
  3. Tabuchi T, Satoh M, Itoh T, Nakamura M. MicroRNA-34a regulates the longevity-associated protein SIRT1 in coronary artery disease: effect of statins on SIRT1 and microRNA-34a expression. Clin Sci. 2012;123(3):161-171.  doi:10.1042/cs20110563
  4. Boon R, Iekushi K, Lechner S et al. MicroRNA-34a regulates cardiac ageing and function. Nature. 2013;495(7439):107-110.  doi:10.1038/nature11919
  5. Lv P, Zhou M, He J et al. Circulating miR-208b and miR-34a Are Associated with Left Ventricular Remodeling after Acute Myocardial Infarction. IJMS. 2014;15(4):5774-5788. doi:10.3390/ijms15045774
  6. Thum T, Gross C, Fiedler J et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456(7224):980-984.  doi:10.1038/nature07511
  7. Sheedy F, Palsson-McDermott E, Hennessy E et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nature Immunology. 2009;11(2):141-147.  doi:10.1038/ni.1828
  8. Zhang Q, Xiao Z, He F, Zou J, Wu S, Liu Z. MicroRNAs Regulate the Pathogenesis of CVB3-Induced Viral Myocarditis Intervirology. 2013;56(2):104-113.  doi:10.1159/000343750
  9. Sabatel C, Malvaux L, Bovy N et al. MicroRNA-21 exhibits antiangiogenic function by targeting RhoB expression in endothelial cells. PLoS ONE. 2011;6(2):e16979. doi:10.1371/journal.pone.0016979
  10. Tijsen A, Creemers E, Moerland P et al. MiR423-5p as a circulating biomarker for heart failure. Circulation Research. 2010;106(6):1035-1039. doi:10.1161/circresaha.110.218297
  11. Goren Y, Kushnir M, Zafrir B, Tabak S, Lewis B, Amir O. Serum levels of microRNAs in patients with heart failure. European Journal of Heart Failure. 2012;14(2):147-154.  doi:10.1093/eurjhf/hfr155
  12. Fan K, Zhang H, Shen J, Zhang Q, Li X. Circulating microRNAs levels in chinese heart failure patients caused by dilated cardiomyopathy. Indian Heart Journal. 2013;65(1):12-16.  doi:10.1016/j.ihj.2012.12.022
  13. van Rooij E, Sutherland L, Qi X, Richardson J, Hill J, Olson E. Control of stress-dependent cardiac growth and gene expression by a MicroRNA. Science. 2007;316(5824):575-579.  doi:10.1126/science.1139089
  14. Wang J, Jiao J, Li Q et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1. Nature Medicine. 2010;17(1):71-78.  doi:10.1038/nm.2282
  15. Shieh J, Huang Y, Gilmore J, Srivastava D. Elevated miR-499 levels blunt the cardiac stress response. PLoS ONE. 2011;6(5):e19481. doi:10.1371/journal.pone.0019481
  16. D'Alessandra Y, Pompilio G, Capogrossi M. Letter by D'Alessandra et al. Regarding Article, «Circulating MicroRNA-208b and MicroRNA-499 Reflect Myocardial Damage in Cardiovascular Disease». Circulation: Cardiovascular Genetics. 2011;4(1):e7-e7.  doi:10.1161/circgenetics.110.958769

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.